Replies to post #111486 on Biotech Values

[microcapfun]

>>I would not rule out a finding of non-inferiority based on those numbers.<<

I'm not ruling it out. I'm just saying it doesn't look likely - at least if the SPA primary endpoint involves ACR20. Incyte's best bet might be to move the primary endpoint to ACR50 - if the FDA goes along.

micro